Matt Gonda, CEO of Amytrx Therapeutics
Two years post-stealth exit, highly secretive inflammation biotech secures final tranche of Series A round
Back in September 2020, a tiny biotech emerged from stealth out of Nashville, calling itself Amytrx Therapeutics and pursuing chronic inflammation. By all measures, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.